Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study
NCT ID: NCT05595135
Last Updated: 2025-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2022-08-15
2023-05-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
NCT02038153
A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia
NCT04694820
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
NCT02892318
Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy
NCT00387647
Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
NCT06954987
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To examine the feasibility, acceptability and preliminary efficacy of txt4AML in a pilot single arm study.
SECONDARY OBJECTIVE:
I. To explore the association between overall treatment responses and real-time oral anti-cancer medication (OAM) adherence.
EXPLORATORY OBJECTIVE:
I. To summarize and assess other patient-reported outcomes, collected either as patient chart review or through self-reported survey, as well as the patient post-intervention interviews.
OUTLINE:
Patients receive interactive text messages to help with adherence to medications and a smart pill bottle with medication reminders on study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Health services research (text messages, smart pill bottle)
Patients receive interactive text messages to help with adherence to medications and a smart pill bottle with medication reminders on study.
Text Message-Based Navigation Intervention
Receive interactive text messaging.
Behavioral, Psychological or Informational Intervention
Receive medication reminders via smart pill bottle
Survey Administration
Ancillary studies
Quality-of-Life Assessment
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Text Message-Based Navigation Intervention
Receive interactive text messaging.
Behavioral, Psychological or Informational Intervention
Receive medication reminders via smart pill bottle
Survey Administration
Ancillary studies
Quality-of-Life Assessment
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients will be or is taking venetoclax (or any other oral anticancer medication) as part of their first line therapy
* Has a phone with text capabilities
* Among patients aged 18 and older we will enroll participants regardless of race or ethnicity
Exclusion Criteria
* Individuals for whom there is documentation of inability to provide consent in the medical record
* Do not speak/read English
* This study will exclude pediatric patients (defined as individuals under age 18 years)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thomas Jefferson University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JT 19501
Identifier Type: OTHER
Identifier Source: secondary_id
22D.340
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.